What's Happening?
Biogen and Ionis have announced the results of a phase 2 clinical trial for their Alzheimer's drug candidate, diranersen. The trial, presented at the Alzheimer's Association International Conference in London, showed that diranersen slowed cognitive decline
by 26% compared to a placebo in patients with early Alzheimer's disease. Despite this promising result, the trial did not meet its primary objective of demonstrating a dose-response relationship. The strongest response was observed with a 60 mg dose administered every six months, while other doses showed less efficacy. This lack of a clear dose-response relationship has led to a decline in Biogen's and Ionis' shares by 8% and 2.5%, respectively. The companies plan to proceed with a phase 3 trial next year.
Why It's Important?
The trial results are significant as they suggest potential for diranersen to be part of a new approach in Alzheimer's treatment, particularly when combined with amyloid-targeting drugs. The ability to target both intracellular and extracellular tau proteins could enhance treatment efficacy. However, the market's reaction indicates investor concerns about the drug's commercial viability, given the lack of a dose-response relationship. This development could impact Biogen's and Ionis' financial performance and influence future investment in Alzheimer's research.
What's Next?
Biogen and Ionis plan to initiate a phase 3 trial for diranersen, which could yield results by the end of the decade. The outcome of this trial will be crucial in determining the drug's future and its potential approval for widespread use. The companies will need to address the dose-response issue to reassure investors and stakeholders about the drug's efficacy and market potential.
